Distribution of innate efflux-mediated aminoglycoside resistance among different Achromobacter species

New Microbes and New Infections

Volumn 10, Issue , 2016, Pages 1-5

  Bador, J ^a   Neuwirth, C ^a   Liszczynski, P ^a   Mezier M C ^a   Chretiennot M ^a   Grenot, E ^a   Chapuis, A ^a   de Curraize, C ^a   Amoureux, L ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

Achromobacter; Aminoglycoside resistance; AxyXY OprZ; Cystic fibrosis; NrdA; Selection pressure

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; GENTAMICIN; NETILMICIN; RNA 16S; TOBRAMYCIN;

ACHROMOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AXYXY OPRZ EFFLUX SYSTEM; BACTERIAL PHENOMENA AND FUNCTIONS; GENE SEQUENCE; MINIMUM INHIBITORY CONCENTRATION; MULTILOCUS SEQUENCE TYPING; NONHUMAN; NOTE; OPERON; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS;

EID: 84954229377     PISSN: 20522975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmni.2015.11.013     Document Type: Note

References (19)

1. Amoureux L., Bador J., Siebor E., Taillefumier N., Fanton A., Neuwirth C. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros 2013, 12:170-176.
2. Emerson J., McNamara S., Buccat A.M., Worrell K., Burns J.L. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010, 45:363-370.
3. Yabuuchi E., Oyama A. Achromobacter xylosoxidans n. sp. from human ear discharge. Jpn J Microbiol 1971, 15:477-481.
4. Yabuuchi E., Kawamura Y., Kosako Y., Ezaki T. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Rüger and Tan) comb. nov. Microbiol Immunol 1998, 42:429-438.
5. Coenye T., Vancanneyt M., Cnockaert M.C., Falsen E., Swings J., Vandamme P. Kerstersia gyiorum gen. nov., sp. nov., a novel Alcaligenes faecalis-like organism isolated from human clinical samples, and reclassification of Alcaligenes denitrificans Rüger and Tan 1983 as Achromobacter denitrificans comb. nov. Int J Syst Evol Microbiol 2003, 53:1825-1831.
6. Coenye T., Vancanneyt M., Falsen E., Swings J., Vandamme P. Achromobacter insolitus sp. nov. and Achromobacter spanius sp. nov., from human clinical samples. Int J Syst Evol Microbiol 2003, 53:1819-1824.
7. Gomila M., Tvrzová L., Teshim A., et al. Achromobacter marplatensis sp. nov., isolated from a pentachlorophenol-contaminated soil. Int J Syst Evol Microbiol 2011, 61:2231-2237.
8. Vandamme P., Moore E.R., Cnockaert M., et al. Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol 2013, 36:1-10.
9. Vandamme P., Moore E.R., Cnockaert M., et al. Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively. Syst Appl Microbiol 2013, 36:474-482.
10. Spilker T., Vandamme P., LiPuma J.J. A multilocus sequence typing scheme implies population structure and reveals several putative novel Achromobacter species. J Clin Microbiol 2012, 50:3010-3015.
11. Spilker T., Vandamme P., LiPuma J.J. Identification and distribution of Achromobacter species in cystic fibrosis. J Cyst Fibros 2013, 12:298-301.
12. Bador J., Amoureux L., Duez J.M., et al. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob Agents Chemother 2011, 55:4912-4914.
13. Bador J., Amoureux L., Blanc E., Neuwirth C. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump. Antimicrob Agents Chemother 2013, 57:603-605.
14. Saiman L., Chen Y., Tabibi S., et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001, 39:3942-3945.
15. Wang M., Ridderberg W., Hansen C.R., et al. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J Cyst Fibros 2013, 12:638-643.
16. Vogne C., Aires J.R., Bailly C., Hocquet D., Plesiat P. Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004, 48:1676-1680.
17. Ridderberg W., Wang M., Nørskov-Lauritsen N. Multilocus sequence analysis of isolates of Achromobacter from patients with cystic fibrosis reveals infecting species other than Achromobacter xylosoxidans. J Clin Microbiol 2012, 50:2688-2694.
18. Barrado L., Brañas P., Orellana M.Á., et al. Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain. J Clin Microbiol 2013, 51:1927-1930.
19. Dupont C., Michon A.L., Jumas-Bilak E., Nørskov-Lauritsen N., Chiron R., Marchandin H. Intrapatient diversity of Achromobacter spp. involved in chronic colonization of cystic fibrosis airways. Infect Genet Evol 2015, 32:214-223.